Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 19/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 13/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.87 |
| ▸ | HTR2B | P41595 | 1/20 | 0.87 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22933145 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL20122154 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL16774394 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL19464994 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL3740313 | 0.93 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL13388428 | 0.93 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL958888 | 0.93 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL29524384 | 0.93 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL958891 | 0.93 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL28525054 | 0.93 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165887-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-06-01 | — | — | US | disclosed |
| US-11484545-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-20220000899-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-01-06 | — | — | US | disclosed |
| US-10953031-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200046751-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-9789131-B1 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953031-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885ADORA1 994/4885ADORA2A 436/4885 |
| US-20200046751-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885ADORA1 994/4885ADORA2A 436/4885 |
| US-11484545-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885ADORA1 994/4885ADORA2A 436/4885 |
| US-20230165887-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885ADORA1 994/4885ADORA2A 436/4885 |
| US-20220000899-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885ADORA1 994/4885ADORA2A 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.